Evgen Pharma plc (EVG) Ordinary 0.25p

- Add to watchlist
- Create an alert
- This stock can be held in a




Business summary
Evgen Pharma plc is a clinical stage drug development company. The Company is developing sulforaphane-based medicines focused on the treatment of cancer and inflammation. The Company's pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The SFX-01 reduces the number of cancer stem cells in patient-derived breast cancer tissue in xenograft models. Its SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin.
Contact details
Important dates
General stock information
- EPIC:
- EVG
- ISIN:
- GB00BSVYN304
- Market cap:
- £9.48 million
- Shares in issue:
- 274.89 million
- Sector:
- Pharmaceuticals & Biotechnology
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.